PMID- 30711972
OWN - NLM
STAT- MEDLINE
DCOM- 20190220
LR  - 20190320
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 39
IP  - 2
DP  - 2019 Feb
TI  - Radiation Therapy for Extrapelvic Lymph Node Recurrence After Curative Treatment 
      for Cervical Cancer.
PG  - 891-895
LID - 10.21873/anticanres.13190 [doi]
AB  - BACKGROUND/AIM: To investigate outcomes of patients with cervical cancer who
      received radiation therapy for extrapelvic lymph node recurrence after initial
      pelvic radiotherapy. PATIENTS AND METHODS: The treatment charts of 20 patients
      were retrospectively reviewed, and factors influencing patient's prognosis were
      statistically analyzed. RESULTS: The three-year in-field tumor control rate was
      55% and overall survival (OS) at 2, 3, and 5 years was 55%, 45%, and 37.5%,
      respectively. The rate of the three-year OS in patients with recurrence within
      and after 9 months was 20% and 70%, respectively (p=0.016). None of the 4
      patients who were diagnosed with supraclavicular lymph node recurrence alone at
      more than 9 months after initial treatment experienced further recurrence.
      Five-year survival of the remaining 16 patients was only 21% (p=0.021).
      CONCLUSION: Time to recurrence significantly influenced survival in patients with
      cervical cancer who received radiotherapy for extra-pelvic lymph node recurrence.
      Supraclavicular lymph node recurrence alone had a favorable impact on patient's
      prognosis.
CI  - Copyright(c) 2019, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Uno, Takashi
AU  - Uno T
AD  - Department of Diagnostic Radiology and Radiation Oncology, Graduate School of
      Medicine, Chiba University, Chiba, Japan unotakas@faculty.chiba-u.jp.
FAU - Kanazawa, Aki
AU  - Kanazawa A
AD  - Department of Diagnostic Radiology and Radiation Oncology, Graduate School of
      Medicine, Chiba University, Chiba, Japan.
FAU - Nemoto, Miho Watanabe
AU  - Nemoto MW
AD  - Department of Diagnostic Radiology and Radiation Oncology, Graduate School of
      Medicine, Chiba University, Chiba, Japan.
FAU - Harada, Rintaro
AU  - Harada R
AD  - Department of Diagnostic Radiology and Radiation Oncology, Graduate School of
      Medicine, Chiba University, Chiba, Japan.
FAU - Kobayashi, Hiroki
AU  - Kobayashi H
AD  - Department of Diagnostic Radiology and Radiation Oncology, Graduate School of
      Medicine, Chiba University, Chiba, Japan.
FAU - Saito, Makoto
AU  - Saito M
AD  - Department of Diagnostic Radiology and Radiation Oncology, Graduate School of
      Medicine, Chiba University, Chiba, Japan.
FAU - Iwai, Yuma
AU  - Iwai Y
AD  - Department of Diagnostic Radiology and Radiation Oncology, Graduate School of
      Medicine, Chiba University, Chiba, Japan.
FAU - Usui, Hirokazu
AU  - Usui H
AD  - Department of Reproductive Medicine, Graduate School of Medicine, Chiba
      University, Chiba, Japan.
FAU - Mitsuhashi, Akira
AU  - Mitsuhashi A
AD  - Department of Reproductive Medicine, Graduate School of Medicine, Chiba
      University, Chiba, Japan.
FAU - Shozu, Makio
AU  - Shozu M
AD  - Department of Reproductive Medicine, Graduate School of Medicine, Chiba
      University, Chiba, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Hysterectomy
MH  - Kaplan-Meier Estimate
MH  - Lymph Nodes/pathology
MH  - Lymphatic Metastasis/*radiotherapy
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/radiotherapy
MH  - Prognosis
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Uterine Cervical Neoplasms/mortality/*radiotherapy
OTO - NOTNLM
OT  - Lymph node recurrence
OT  - cervical cancer
OT  - radiation therapy
EDAT- 2019/02/04 06:00
MHDA- 2019/03/21 06:00
CRDT- 2019/02/04 06:00
PHST- 2018/11/13 00:00 [received]
PHST- 2019/01/06 00:00 [revised]
PHST- 2019/01/07 00:00 [accepted]
PHST- 2019/02/04 06:00 [entrez]
PHST- 2019/02/04 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
AID - 39/2/891 [pii]
AID - 10.21873/anticanres.13190 [doi]
PST - ppublish
SO  - Anticancer Res. 2019 Feb;39(2):891-895. doi: 10.21873/anticanres.13190.